1. Galectin-9 as a new biomarker of acute-on-chronic liver failure
- Author
-
Jun Ling, Shaoli You, Weiwei Chen, Xinxin Yang, Yiwen Xv, and Bing Zhu
- Subjects
Gal-9 ,ACLF ,Prognosis ,Clinical diagnosis ,Hepatology ,Medicine ,Science - Abstract
Abstract Galectin-9 (Gal-9) expression in patients with acute-on-chronic liver failure and its correlation with prognosis remain unclear. This study investigated the relationship between liver failure prognosis and Gal-9 expression analysis in patients with acute-on-chronic liver failure. Patients with acute-on-chronic liver failure attributable to hepatitis B and those with chronic hepatitis B were included in this single-center prospective cohort study. The Gal-9 levels in the acute-on-chronic liver failure group were significantly higher than those in the chronic hepatitis B group, and there was an upregulation of Gal-9 and T-cell immunoglobulin domain and mucin domain-3 expressions in peripheral blood T cells. Gal-9 was localized in the regenerative areas of liver tissues in patients with acute-on-chronic liver failure, co-localizing with Kupffer cells. Kaplan–Meier survival curves showed that patients with Gal-9 levels
- Published
- 2024
- Full Text
- View/download PDF